BioIntelliSense Biobutton-C wins FCC Approval for remote health monitoring

BioIntellisense biobutton

BiointelliSense has been making a name for itself in the area of continuous health monitoring and clinical intelligence platform. The company’s latest Biobutton-C has been approved by the FCC equipment authorization today.

The BioIntelliSense Data-as-a-Service (DaaS) platform and FDA-cleared BioSticker™ on-body sensor are bringing medical-grade monitoring and management to the home for scalable remote care clearly making BioIntelliSense a serious contender in the emerging remote health monitoring space.

The Biobutton system is a scalable and cost-effective solution for COVID-19 symptom monitoring at school, home, and work:

  • FDA-cleared medical-grade wearable for continuous vital sign monitoring for up to 90-days
  • Discreet, coin-sized, single-use disposable design for an effortless user experience
  • Continuous temperature, respiratory rate and heart rate at rest measurements
  • BioMobile™ daily health screening surveys based on CDC guidelines
  • Non-location based contact tracing capability and reporting
  • Health data protection through strict privacy and security safeguards

It’s not exactly clear from the filing if the new BioButton-C product is the existing Covid-19 monitoring platform or is a completely new product. Since the product description has a ‘C’ suffix to it, we think that its the company’s product for monitoring Covid-19.

As businesses begin to slowly open up, there is going to be a new protocol around workplace safety that involves testing and symptom tracking. 

Remote monitoring services

This provides BioIntelliSense with an opportunity to assist the business community by offering its remote monitoring services, particularly now that we know that temperature-based checks have proven to be unreliable.

The company has partnered up with established medical players such as Philips this summer in an effort to position itself in the emerging remote health monitoring space. Philips is leveraging the BioSticker product into its remote monitoring platform.

Remote patient monitoring and telehealth-enabled clinical programs offer care teams a sustainable and scalable way to manage patient populations with chronic or complex conditions at home and plays a key role in supporting care for COVID-19 patients who do not require hospitalization.

As an Amazon Associate MyHealthyApple may earn commissions from qualifying purchases using our links

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.